3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Multiple Myeloma
26
Leukemia, Myeloid, Acute
24
Recurrence
12
Sarcoma
7
Lymphoma, Large B-Cell, Diffuse
6
Neoplasm Metastasis
5
Neurofibrosarcoma
4
Neoplasms, Plasma Cell
4
Lymphoma
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Thymoma
2
Rhabdoid Tumor
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Liposarcoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Congenital Abnormalities
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Breast Neoplasms
2
Wilms Tumor
1
Interventions
Cisplatin
7
Etoposide
6
Amifostine
6
Radiotherapy
5
Drug Therapy
5
Cyclophosphamide
5
apatinib
4
Methotrexate
4
Filgrastim
4
Cytarabine
4
sodium thiosulfate
3
Methylprednisolone
3
Carboplatin
3
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Nivolumab
2
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
selinexor
1
sargramostim
1
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Drug-Related Side Effects and Adverse Reactions
×
selinexor
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled